BiotechTube
Spectral AI

Spectral AI

Dallas, United States· Est.
spectral-ai.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $25M

Overview

Spectral AI is a Dallas-based medical technology company founded in 2019, focused on transforming wound care through AI-driven predictive analytics. Its DeepView System uses multispectral imaging and machine learning to generate a binary healing prediction for wounds like diabetic foot ulcers on day one of assessment, aiming to improve clinical outcomes and reduce costs. The technology is currently investigational, backed by a substantial intellectual property portfolio of 26 patents, and is positioned to address a significant unmet need in chronic wound management.

Wound CareDiabetic Foot UlcersBurn Care

Technology Platform

Proprietary platform combining multispectral imaging (MSI) to capture sub-surface tissue data with artificial intelligence (AI) algorithms trained to predict wound healing outcomes. Outputs a binary (heal/not heal) prediction on day one of assessment.

Funding History

2
Total raised:$25M
Series B$15M
Series A$10M

Opportunities

The global diabetic foot ulcer and chronic wound market represents a multi-billion dollar opportunity with a high unmet need for objective, predictive diagnostics.
Successful FDA clearance could enable rapid adoption by clinicians and payers seeking to improve outcomes and reduce costly complications like amputations.
The platform technology is also extensible to other wound types and tissue health applications.

Risk Factors

The company faces significant regulatory risk as its lead product is an investigational device pending FDA clearance.
Clinical validation in pivotal trials is non-guaranteed, and market adoption requires changing established clinical practices.
Competition from other digital wound care companies is also a material risk.

Competitive Landscape

Spectral AI competes in the emerging digital wound assessment space, which includes companies like eKare, WoundVision, and Tissue Analytics, as well as R&D efforts by large medtech firms in advanced wound care. Its differentiation lies in the specific combination of multispectral imaging for sub-surface data and an AI algorithm designed for a binary, immediate healing prediction.

More companies in Diagnostics & Precision Medicine →More companies in United States →